Chimerix, a Durham-based firm, has received a $36 million grant from the National Institute of Allergy and Infectious Diseases to develop an oral smallpox vaccine plus an additional $3.1 million in financing, according to media reports.

The News & Observer reported Tuesday that Chimerix will get the federal grant over a period of four years.

Sanderling Ventures and Asset Management invested $3.1 million, according to the Triangle Business Journal.